Evaluation of an Influenza Vaccination Implementation Strategy for Hospital Health Care Workers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01481467|
Recruitment Status : Unknown
Verified December 2011 by Josien Riphagen-Dalhuisen, University Medical Center Groningen.
Recruitment status was: Recruiting
First Posted : November 29, 2011
Last Update Posted : December 20, 2011
Influenza is a serious disease which can cause severe illness and even death among patients. Health care workers (HCWs) often get infected with influenza and up to 76% of them keep working while being ill. Immunizing HCWs is therefore an essential factor in protecting patients from influenza as HCWs easily transmit influenza to their patients.
However, despite recommendations from the Dutch Health Council since 2007, vaccine uptake among HCWs remains low.
The aim of this study is to develop an effective implementation strategy on the basis of previous behavioural studies and to evaluate its value in a clustered randomized trial in all Dutch University Medical Centers (UMCs). Also, we want to assess the program elements that are associated with a higher vaccine uptake and the cost-effectiveness of such an implementation strategy.
The results of this study will give more insights in the way influenza vaccination campaigns should be directed in order to achieve high vaccine uptake rates among HCWs in hospitals.
|Condition or disease||Intervention/treatment||Phase|
|Influenza||Behavioral: Influenza vaccination implementation strategy||Not Applicable|
Since influenza vaccination rates among hospital HCWs are low, we developed an implementation program which will be tested in this large target group. The primary objective is to evaluate the short- and long-term effects of a multi-faceted implementation program to improve influenza vaccine uptake among HCWs in hospitals over two influenza seasons. Its clinical effects are assessed by means of a randomized controlled trial in selected divisions (e.g. internal medicine, pediatric ward) of all six randomized UMCs in the Netherlands. Secondary aims are to assess program elements associated with higher vaccine uptake among the target group and to evaluate the cost-effectiveness of the program.
The program will be developed using the Intervention Mapping method taking into account all evidence from systematic literature review and the questionnaire study among HCWs in UMCs as part of our before measurement (2008). The Intervention Mapping method is a theoretical framework developed in the field of health education and promotion to systematically design theory and evidence based health promotion programs.
In 2008, we have selected five divisions of all UMCs that will take part in the trial. Before measurement showed wide variation of uptake (<15-50%) and 11 determinants that explained more than 95% of the vaccination behaviour. Three UMCs will adopt the intervention developed by the research group using the Intervention Mapping method, and three UMCs will serve as controls. The current implemented programs in the UMCs vary widely ranging from passive information systems to involvement of the Board of Directors. Our intervention will exist of a multi-faceted program aimed at both HCWs and management of the divisions. Our primary outcome will be the recorded vaccine uptake among HCWs in the UMCs.
To evaluate the short-term and long-term process of the program, web-based questionnaires will be developed and directed at all health care workers of the selected divisions in all UMCs. The questionnaire will contain questions about vaccine uptake and HCWs' opinions on influenza, vaccination and the vaccination campaign. Absenteeism will also be registered.
Finally, patient data will be collected in the participating divisions of all UMCs in order to investigate if there is a relationship between vaccinating HCWs and morbidity and mortality in patients because of influenza.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||6 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Evaluation of a Multi-faceted Influenza Vaccination Implementation Strategy for Health Care Workers in Hospitals|
|Study Start Date :||April 2009|
|Estimated Primary Completion Date :||December 2011|
|Estimated Study Completion Date :||March 2012|
Influenza vaccination implementation strategy applied.
Behavioral: Influenza vaccination implementation strategy
A multi-faceted influenza vaccination implementation strategy
No Intervention: Control
- Influenza vaccine uptake among health care workers in the UMCs [ Time Frame: Up to 2 months ]Influenza vaccine uptake among health care workers of all UMCs. Measured by means of data provided by the departments of occupational health. For the assessment of short-term effects vaccine uptake is measured after the first influenza season (2009/2010) in February-March 2010 and for the long-term effects it is measured after the second influenza season (2010/2011) in March-April 2011.
- Absenteeism among health care workers during influenza epidemics [ Time Frame: Up to 5 months ]Absenteeism among HCWs is assessed by means of data provided by the department of occupational health at the end of both influenza seasons.
- Patient morbidity and mortality [ Time Frame: Up to 5 months ]After the second influenza season (2010/2011) patient data are collected from selected departments of both the intervention and control UMCs. It is measured by assessing if patients had influenza, if they were tested on influenza, if they had developed a pneumonia, if they were admissioned to the intensive care unit, the duration of hospitalization and intensive care admission and finally mortality.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01481467
|Contact: Josien Riphagen-Dalhuisen, MD||+31 (0)6 45 23 80 email@example.com|
|Contact: Eelko Hak, PhD||+31 (0)50 363 firstname.lastname@example.org|
|University Medical Centre Groningen||Completed|
|Groningen, Netherlands, 9700 RB|
|University Medical Centre||Recruiting|
|Groningen, Netherlands, 9700 RB|
|Principal Investigator:||Josien Riphagen-Dalhuisen, MD||University Medical Centre Groningen/ University of Groningen|
|Study Director:||Eelko Hak, PhD||University Medical Centre Groninge/University of Groningen|